| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 1/10-1/50 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Krueppel-like factor 6, B-cell-derived protein 1, Core promoter element-binding protein, GC-rich sites-binding factor GBF, Proto-oncogene BCD1, Suppressor of tumorigenicity 12 protein, Transcription factor Zf9, KLF6, BCD1, COPEB, CPBP, ST12 |
| Entrez GeneID | 1316 |
| WB Predicted band size | 31.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This KLF6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 159-186 amino acids from the C-terminal region of human KLF6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于KLF6抗体的3篇文献示例(注：文献标题和作者为虚拟示例，仅供格式参考)：
1. **文献名称**：*KLF6 Suppresses Hepatocellular Carcinoma Proliferation by Transcriptional Regulation of p21*
**作者**：Smith A, et al.
**摘要**：通过Western blot和免疫组化(使用KLF6多克隆抗体)发现，KLF6在肝癌组织中表达下调，其过表达可通过激活p21抑制肿瘤细胞增殖。
2. **文献名称**：*KLF6 Somatic Mutations Promote Prostate Tumorigenesis via Loss of Tumor Suppression*
**作者**：Brown L, et al.
**摘要**：研究利用KLF6抗体检测前列腺癌患者组织样本，发现KLF6基因突变导致蛋白表达缺失，促进肿瘤进展和转移。
3. **文献名称**：*KLF6 Modulates Fibrotic Response in Hepatic Stellate Cells*
**作者**：Chen Y, et al.
**摘要**：通过免疫荧光(使用抗KLF6单克隆抗体)证实KLF6在肝纤维化中负调控TGF-β信号通路，抑制星状细胞活化。
4. **文献名称**：*KLF6 Regulates Adipocyte Differentiation through PPARγ Activation*
**作者**：Kim J, et al.
**摘要**：研究使用KLF6抗体进行ChIP实验，发现KLF6直接结合PPARγ启动子，调控脂肪细胞分化过程。
(注：以上文献为示例，实际引用需检索PubMed等数据库获取真实文献。)
**Background of KLF6 Antibody**
The Krüppel-like factor 6 (KLF6) is a member of the Krüppel-like transcription factor family, characterized by zinc finger DNA-binding domains. It plays critical roles in regulating cellular processes such as proliferation, differentiation, apoptosis, and angiogenesis. KLF6 is broadly expressed in tissues and acts as a tumor suppressor by modulating genes involved in cell cycle control (e.g., p21) and inhibiting oncogenic signaling pathways. Dysregulation of KLF6. through mutations, loss of heterozygosity, or epigenetic silencing, is implicated in various cancers, including prostate, liver, and colorectal cancer, as well as non-cancerous conditions like fibrosis and metabolic disorders.
KLF6 antibodies are essential tools for detecting and quantifying KLF6 protein levels in research and diagnostic settings. These antibodies enable the study of KLF6's expression patterns, subcellular localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific KLF6 antibodies can distinguish between full-length KLF6 and its splice variants (e.g., KLF6-SV1), which often exhibit opposing biological functions. Reliable antibodies are critical for elucidating KLF6's role in disease mechanisms, therapeutic targeting, and biomarker development. Their validation ensures accuracy in both basic research and clinical applications, supporting advances in understanding KLF6-associated pathologies.
×
